Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease

被引:17
作者
Panizo, Nayara [1 ]
Goicoechea, Marian [1 ]
Garcia de Vinuesa, Soledad [1 ]
Arroyo, David [1 ]
Yuste, Claudia [1 ]
Rincon, Abraham [1 ]
Verdalles, Ursula [1 ]
Ruiz-Caro, Caridad [2 ]
Quiroga, Borja [1 ]
Luno, Jose [1 ]
机构
[1] Hosp Gen Univ Gregorio Maranon, Serv Nefrol, Madrid 28007, Spain
[2] Clin Dialctr, Madrid, Spain
来源
NEFROLOGIA | 2012年 / 32卷 / 02期
关键词
Polycystic Kidney Diseases; BLOOD-PRESSURE; RENAL-FUNCTION; HYPERTENSION; RISK; POPULATION; PREVENTION; GUIDELINES; DIAGNOSIS; SURVIVAL; CRISP;
D O I
10.3265/Nefrologia.pre2011.Dec.11177
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The aim of this study was to analyse the factors influencing chronic kidney disease (CKD) progression in patients with autosomal dominant polycystic kidney disease (ADPKD). Material and Method: We studied 101 patients (mean age: 43 +/- 17.3 years, 43.56% male) followed during a median (interquartile range) follow-up time of 69 (35-128) months from 1997 to 2010. The primary end point was: time to a 50% decrease of estimated glomerular filtration rate (eGFR) (CKD-EPI) since the first-time visit and/or time to initiation of renal replacement therapy. The mean anual eGFR change was also analysed. Clinical and demographic data, blood pressure, concomitant medications, and analytical parameters were collected at each visit. Baseline kidney size was also recorded by ultrasound. Results: Thirty-one patients achieved the primary end point after a median (IQR) time of 102 (53-131) months. Those patients who achieved the primary end point had higher SBP and DBP (P=0.017 and P=0.001), higher LDL-cholesterol (P=0.011), higher creatinine (P=0.006), higher uricemia (P=0.041), more severe proteinuria (P=0.033) and greater kidney size (P=0.05). The mean annual eGFR change was of -3.52 +/- 7.3ml/min/1.73m(2). Forty-nine patients had a rapid decline in renal function: Group A (higher than - 3.52ml/min/1.73m(2)) and 52 patients had a lower renal disease progression: Group B (<-3.2 ml/min/1.73 m(2)). Adjusted Cox regression analysis showed that higher SBP and younger age at the first visit were independent variables for poorer renal outcome (P=0.026). Conclusions: Initial kidney function, proteinuria, renal size, hypercholesterolemia, hyperuricemia, and SBP are the factors that influence CKD progression in ADPKD. SBP and younger age at diagnosis are the only factors that maintain their independent predictive value in a multivariant analysis.
引用
收藏
页码:197 / 205
页数:9
相关论文
共 51 条
[31]   European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish Adaptation [J].
Lobos, J. M. ;
Royo-Bordonada, M. A. ;
Brotons, C. ;
Alvarez-Sala, L. ;
Armario, P. ;
Maiques, A. ;
Mauricio, D. ;
Sans, S. ;
Villar, F. ;
Lizcano, A. ;
Gil-Nunez, A. ;
de Alvaro, F. ;
Conthe, P. ;
Luengo, E. ;
del Rio, A. ;
Cortes, O. ;
de Santiago, A. ;
Varga, M. A. ;
Martinez, M. ;
Lizarbe, V. .
REVISTA CLINICA ESPANOLA, 2009, 209 (06) :279-302
[32]   2005 Spanish guidelines in diagnosis and treatment of arterial hypertension [J].
Marín, R ;
de la Sierra, A ;
Armario, P ;
Campo, C ;
Banegase, JR ;
Gorostidi, M .
MEDICINA CLINICA, 2005, 125 (01) :24-34
[33]   Early Renal Abnormalities in Autosomal Dominant Polycystic Kidney Disease [J].
Meijer, Esther ;
Rook, Mieneke ;
Tent, Hilde ;
Navis, Gerjan ;
van der Jagt, Eric J. ;
de Jong, Paul E. ;
Gansevoort, Ron T. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (06) :1091-1098
[34]   Changes in Urinary Albumin Excretion, Inflammatory and Oxidative Stress Markers in ADPKD Patients with Hypertension [J].
Nakamura, Tsukasa ;
Sato, Eiichi ;
Fujiwara, Nobuharu ;
Kawagoe, Yasuhiro ;
Yamada, Shingo ;
Ueda, Yoshihiko ;
Koide, Hikaru .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2012, 343 (01) :46-51
[35]   Improved Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease in Denmark [J].
Orskov, Bjarne ;
Sorensen, Vibeke Romming ;
Feldt-Rasmussen, Bo ;
Strandgaard, Svend .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (11) :2034-2039
[36]   Use of Antihypertensive Medications and Mortality of Patients With Autosomal Dominant Polycystic Kidney Disease: A Population-Based Study [J].
Patch, Christine ;
Charlton, Judith ;
Roderick, Paul J. ;
Gulliford, Martin C. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57 (06) :856-862
[37]   Influence of VEGF Polymorphism on Progression of Autosomal Dominant Polycystic Kidney Disease [J].
Reiterova, J. ;
Obeidova, H. ;
Lenicek, M. ;
Stekrova, J. ;
Merta, M. ;
Maixnerova, D. ;
Vitek, L. ;
Viklicky, O. ;
Tesar, V. .
KIDNEY & BLOOD PRESSURE RESEARCH, 2008, 31 (06) :398-403
[38]   Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease [J].
Ruggenenti, P ;
Remuzzi, A ;
Ondei, P ;
Fasolini, G ;
Antiga, L ;
Ene-Iordache, B ;
Remuzzi, G ;
Epstein, FH .
KIDNEY INTERNATIONAL, 2005, 68 (01) :206-216
[39]   Relationship between kidney size and blood pressure profile in patients with autosomal dominant polycystic kidney disease without renal failure [J].
Sans Atxer, L. ;
Roca-Cusachs, A. ;
Torra, R. ;
Calero, F. ;
Arias, P. ;
Ballarin, J. ;
Fernandez-Llama, P. .
NEFROLOGIA, 2010, 30 (05) :567-572
[40]   Implications of Proteinuria: CKD Progression and Cardiovascular Outcomes [J].
Sarnak, Mark J. ;
Astor, Brad C. .
ADVANCES IN CHRONIC KIDNEY DISEASE, 2011, 18 (04) :258-266